Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Clinical trial NCT06130254 · TERMINATED
Trial details
- NCT number
- NCT06130254
- Sponsor
- M.D. Anderson Cancer Center
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-30
- Primary completion
- 2024-06-14
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.